Azilva (azilsartan) / Takeda - LARVOL DELTA

Azilsartan Ameliorates Diabetic Kidney Disease Through Modulation of Inflammation, Pyroptosis, and Mitochondrial Dysfunction. (PubMed, J Diabetes Res) - "AZL improves renal function and pathology in DKD mice, potentially through both hemodynamic (blood pressure lowering) and nonhemodynamic mechanisms. In vitro evidence indicates that AZL suppresses HG-induced mesangial cell pyroptosis by inhibiting mtROS generation and NLRP3 inflammasome activation."

Journal • Diabetes • Diabetic Nephropathy • Inflammation • Metabolic Disorders • Nephrology • Renal Disease • CASP1 • IL1B • NLRP3

Six-month renal marker trajectories with azilsartan–indapamide versus azilsartan–nitrendipine in essential hypertension: a pragmatic comparative study (ESC 2026) - "Conclusion In this pragmatic comparative cohort, azilsartan combined with either indapamide or nitrendipine demonstrated similar short-term improvements in eGFR and reductions in microalbuminuria. The choice of add-on agent did not meaningfully alter short-term renal trajectory under azilsartan-based therapy."

Cardiovascular • Hypertension

Differential effects of azilsartan-based combinations on arterial stiffness and central hemodynamics in essential hypertension (ESC 2026) - "The comparative impact of different azilsartan-based combinations on structural and pulsatile components of vascular stiffness remains insufficiently explored.AimTo compare the effects of azilsartan plus nitrendipine (A+N) versus azilsartan plus indapamide (A+I) on carotid–femoral pulse wave velocity (cfPWV), central pulse pressure (cPP), and augmentation index (AIx) in patients with essential hypertension.MethodsIn this prospective comparative study, patients with essential hypertension received A+N (n=51) or A+I (n=50) for 6 months.Carotid–femoral PWV and central hemodynamic parameters were assessed at baseline and at 6 months using applanation tonometry. Within-group changes and between-group differences in delta values were analyzed.ResultsBoth treatment regimens were associated with significant reductions in cfPWV.In the A+N group, PWV decreased from 10.57 m/s to 7.37 m/s (Δ −3.20 m/s; p<0.000001).In the A+I group, PWV decreased from 9.59 m/s to 7.36 m/s (Δ −2.23..."

Cardiovascular • Hypertension

Vascular stiffness–integrated ai model improves discrimination of poor responders to azilsartan–indapamide therapy (ESC 2026) - "An interpretable AI model integrating vascular stiffness and metabolic/renal parameters improves identification of poor responders to azilsartan–indapamide beyond baseline SBP and supports precision phenotyping with feasible offline bedside deployment."

Cardiovascular • Hypertension

Emerging Pharmacological Therapies for Hypertension. (PubMed, Curr Hypertens Rev) - "This review provides a general overview of the physiological effects and pharmacokinetic properties that affect the absorption, distribution, metabolism, and elimination of recently developed antihypertensive drugs, such as fimasartan, azilsartan, zilebesiran, aprocitentan, and esaxerenone. Mechanistic differences among these agents are also highlighted; for instance, fimasartan and azilsartan inhibit the angiotensin II receptor, whereas other medications alter mineralocorticoid activity or endothelial pathways. The review further discusses the clinical implications of these mechanisms in hypertension management and supports informed therapeutic decisionmaking by providing a detailed understanding of the pharmacological and mechanistic profiles of these emerging antihypertensive therapies."

Journal • Cardiovascular • Hypertension

Identification of hypertension-associated bacterial key genes as potential targets and therapeutic agents through integrated bioinformatics approach. (PubMed, Int Microbiol) - "Structure-based molecular docking identified five approved drugs, namely Azilsartan, Eplerenone, Candesartan, Conivaptan, and Telmisartan, as top-ranked compounds exhibiting strong binding affinities toward the proposed targets. Therefore, this study identifies microbial gene signatures potentially involved in HTN and proposes a microbiome-guided drug repurposing strategy targeting bacterial functional pathways. These findings provide novel insights into microbiota-host interactions in HTN and highlight promising therapeutic candidates that warrant further experimental and clinical validation."

Journal • Cardiovascular • Hypertension

Development of IgA nephropathy following risankizumab therapy for psoriatic arthritis: a case report. (PubMed, CEN Case Rep) - "Despite supportive therapy with azilsartan and dapagliflozin, kidney function continued to worsen and proteinuria persisted, prompting a percutaneous kidney biopsy in February 2025. We administered steroid pulse therapy according to the Pozzi protocol (methylprednisolone 500 mg/day for 3 consecutive days), achieving remission of urinary abnormalities with modest improvement in kidney function, while risankizumab was continued. This case highlights the need for periodic urinalysis and kidney function monitoring during IL-23-targeted therapy and suggests that IgAN-directed treatment may be effective even when continuation of the biologic agent is clinically necessary."

Journal • Glomerulonephritis • IgA Nephropathy • Immunology • Inflammatory Arthritis • Psoriasis • Psoriatic Arthritis • Renal Disease • Rheumatology • Seronegative Spondyloarthropathies • IL23A

Paraxanthine and azilsartan attenuate gentamicin-induced renal fibrosis via modulation of TGF-β1/Smad3/7 signaling and miRNA-21/miRNA-200b expression. (PubMed, J Transl Med) - "Paraxanthine and azilsartan demonstrated significantl restoring of kidney function and suppressing fibrotic progression. Their actions were mediated through regulation of Smad3/7 signaling and modulation of miRNA-21 and miRNA-200b expression, highlighting these pathways as promising therapeutic targets for the treatment of renal fibrosis."

Journal • Chronic Kidney Disease • Fibrosis • Immunology • Nephrology • Renal Disease • CTGF • KIM1 • MIR21 • SMAD2 • SMAD3 • SMAD7 • TGFB1

Cytokine Toxicity and Bacterial Dysbiosis in Chemotherapy- and/or Radiotherapy-Induced Oral Mucositis: Pathophysiological Mechanisms and Therapeutic Interventions. (PubMed, Life (Basel)) - "Anti-inflammatory agents, including pentoxifylline, atorvastatin, trans-caryophyllene, azilsartan, recombinant human IL-11, and low-level laser therapy have been shown in preclinical models to reduce cytokine levels and promote mucosal healing. Similarly, microbiome-targeted approaches, such as oral microbiota transplantation and multi-strain probiotic formulations, have demonstrated potential in restoring microbial balance and attenuating CRIOM severity, with current evidence including both preclinical and clinical studies. Overall, current findings highlight cytokine toxicity and dysbiosis as synergistic drivers of CRIOM and support anti-inflammatory and microbiome-modulating strategies as promising adjunctive approaches; however, further well-designed clinical studies are required to validate their efficacy and guide clinical translation."

Journal • Review • Head and Neck Cancer • Mucositis • Oncology • Solid Tumor • Stomatitis • Transplantation • IL1B • IL6

Study on the bioequivalence of valsartan potassium tablets in humansunder fed condition (ChiCTR) - P=N/A | N=36 | Completed | Sponsor: The Second Affiliated Hospital Of Xingtai Medical College; The Second Affiliated Hospital Of Xingtai Medical College

New trial • Cardiovascular • Hypertension

A CASE OF LATE-ONSET NEPHROTIC-RANGE PROTEINURIA CAUSED BY AN ANTI-ANGIOGENIC THERAPY FOR METASTATIC BREAST CANCER (ISN-WCN 2026) - "After changing to epirubicin/cyclophosphamide (EC) regimen, the patient's condition had been rather stable after 6 courses of EC therapy, when nausea and general malaise developed and worsened. Then, the regimen was changed to weekly paclitaxel plus bevacizumab (PTX/BEV) therapy...Because it was considered Grade 3 adverse events due to anti-angiogenic therapy, BEV was discontinued and the patient was followed with azilsartan and dapagliflozin...Conclusion The adverse events due to anti-angiogenic therapy are reported to be high, with proteinuria (∼10% to 60%) and hypertension being most prevalent. The interval between initiation of the therapy and the onset of proteinuria varies significantly (several weeks to ∼1 year), but the present case exhibited apparent proteinuria after 80 weeks of therapy. It is important to continuously follow up with close attention to renal function and urinalysis during and after anti-angiogenic therapy, even when the patient has remained..."

Clinical • Metastases • Breast Cancer • Hypertension • Nephrology • Oncology • Renal Disease • Solid Tumor

Newfangled Combination Azilsartan and Ceftriaxone Exhibited Potential Effects in In-Vitro and In-Vivo Models of Cerebral Ischemia: A Comprehensive Pharmacological Investigation. (PubMed, Ann Neurosci) - "The above combination significantly reversed the behavioural dysfunction in ischemic rats, which evidences the beneficial effects. The repurposing of anti-hypertensive, Azi, and antibiotic Cef combination demonstrated an excellent neuroprotective potential, mediating through ameliorating neuroinflammation, excitotoxicity and oxidative stress in in vitro OGD-induced astrocyte-neuron co-culture as well as cerebral ischemic rat model."

Journal • Preclinical • Cardiovascular • CNS Disorders • Inflammation

Efficacy and Safety of Sacubitril/Valsartan After Switching From Azilsartan in Essential Hypertensive Patients: Based on Home Blood Pressure Monitoring. (PubMed, J Clin Hypertens (Greenwich)) - "Twenty-one out of 27 patients accomplished recording of their nighttime HBP, and the morning-nighttime difference in systolic HBP was decreased (8.8 ± 13.5 to 3.9 ± 8.5 mmHg)(all p < 0.05 by repeated-measures ANOVA). In hypertensive patients, sacubitril/valsartan was generally well tolerated, except for causing hypotension, effectively controlled out-of-office BP, and decreased NT-proBNP."

Journal • Hypotension • NPPB

Identification of a Metastatic Clone in Human Undifferentiated Pleomorphic Sarcoma Reveals a Metastasis-Suppressing Therapy (AAOS 2026) - "This study provides direct evidence that a metastatic-clone subpopulation exists in human UPS tumors and is responsible for metastatic dissemination. Targeting AGTR2, a gene selectively expressed in this population, effectively suppresses metastasis in preclinical models. These findings suggest that therapies directed at metastatic subpopulations—using FDA-approved agents like Azilsartan—may represent a promising strategy to improve outcomes for patients with this otherwise difficult to treat sarcoma."

IO biomarker • Metastases • Cardiovascular • Hypertension • Lung Cancer • Sarcoma • Solid Tumor • Undifferentiated Pleomorphic Sarcoma • ESM1

Azilsartan prevents central modulation of BDNF and PPARγ in Alzheimer's pathology through amyloidogenic and inflammatory pathways: experimental and computational evidence. (PubMed, Inflammopharmacology) - "The results demonstrated that intranasal delivery of azilsartan significantly ameliorated cognitive decline when compared to standard drug donepezil, as evidenced from the behavioural tests, restored hippocampal oxidative balance (SOD, GSH, CAT), reduced lipid peroxidation (2.6-fold reduction in MDA levels compared to the AlCl3-intoxicated group), and increased neuronal count. To validate these findings, in silico molecular docking and dynamics simulations were conducted on the key markers TNFα, IL1β, PPARγ, BDNF, APP, and p-Tau, which showed strong and stable binding interactions with BDNF and PPARγ and moderate but persistent stabilization with APP and p-Tau, aligning with in vivo experimental outcomes. Therefore, the integrated computational and experimental evidence thus demonstrates that azilsartan exhibits neuroprotection, highlighting its potential as a therapeutic candidate for repurposing in Alzheimer's disease."

Journal • Alzheimer's Disease • CNS Disorders • Dementia • BDNF • IL1B • PPARG • TNFA

Azilsartan as a novel anti-ferriptotic agent via the upregulation of the Nrf2/HO-1/SLC7A11/GPX4 axis and downregulation of inflammatory pathways in folic acid-induced acute kidney injury in male mice. (PubMed, Toxicol Rep) - "Azilsartan confers potent protection against FA-induced AKI by activating the Nrf2/HO-1/SLC7A11/GPX4 axis, reducing lipid peroxidation, normalizing iron metabolism, and attenuating inflammation. These findings support azilsartan's potential as a repurposed therapy for ferroptosis-driven renal injury."

Journal • Preclinical • Acute Kidney Injury • Inflammation • Nephrology • Renal Disease • GPX4 • KIM1 • SLC7A11 • TFRC • TNFA

A Prospective Comparison of Azilsartan and Amlodipine for Bevacizumab-induced Hypertension and Proteinuria in Colorectal Cancer. (PubMed, In Vivo) - "These findings emphasize that adequate BP control, rather than antihypertensive class, may be critical in managing Bev-induced proteinuria."

Clinical • Journal • Cardiovascular • Colorectal Cancer • Hypertension • Oncology • Renal Disease • Solid Tumor

Encapsulation-based enhancements in modern drug delivery systems. (PubMed, Int J Pharm) - "In addition, the pharmaceutical industry has commercialized many encapsulated drugs, such as anti-inflammatory (ibuprofen, dexamethasone), high blood pressure drugs (valsartan, azilsartan), proton pump inhibitors (lansoprazole), anti-cancer (carboplatin, carmustine, cisplatin, trastuzumab, cytarabine, paclitaxel, doxorubicin (DOX), vincristine) antiparasitic (amphotericin), antifungal (clotrimazole), and hormonal (melatonin (MLT))). It can render drugs more convenient and user-friendly for various therapeutic purposes and help to enhance their performance, functionality, and effectiveness. This comprehensive review examines the encapsulation technologies employed in the pharmaceutical industry, highlighting notable examples of encapsulated drugs that demonstrate their mechanism of action and potential therapeutic effects in vitro, in vivo, and through clinical trials, with relevance to various diseases."

Journal • Review • Cardiovascular • Hypertension • Oncology

Decoding the Neuroprotective Intervention of Angiotensin Receptor Blockers: A Multimodal Approach Using In Silico Network Pharmacology, Molecular Modeling, and In Vivo Validation of Key Markers. (PubMed, ACS Chem Neurosci) - "Building on these findings, this study sought to compare the activity of azilsartan with other commonly used ARBs, including telmisartan, olmesartan, valsartan, eprosartan, irbesartan, and candesartan, using an integrative network pharmacology approach. To experimentally validate these predictions, in vivo studies were conducted in a scopolamine-induced memory-impaired model, which demonstrated significant restoration of the levels of AKT1 and PIK3CA. These findings clearly demonstrate the PI3K/AKT modulating effects of azilsartan, reinforcing its repurposing potential in dementia and related disorders, thereby expanding novel therapeutic opportunities within this drug class."

Journal • Preclinical • Alzheimer's Disease • CNS Disorders • Dementia • AKT1 • PIK3CA • PIK3CB

Azilsartan as an antihypertensive treatment in Japanese children under 6 years old: A phase 3 open-label long-term study. (PubMed, Pediatr Int) - "Azilsartan was generally well tolerated and associated with sustained BP reductions over 52 weeks in nine Japanese pediatric patients with hypertension. No new safety signals were identified. Our results indicate that azilsartan can be a therapeutic option for managing pediatric hypertension, potentially improving long-term cardiovascular outcomes."

Journal • P3 data • Acute Kidney Injury • Cardiovascular • Hematological Disorders • Hypertension • Nephrology • Pediatrics • Renal Disease

Acute Kidney Injury from Mononuclear Cell-Predominated Interstitial Nephritis After Introduction of a Glucagon-Like Peptide-1 Receptor Agonist: A Case Report. (PubMed, Am J Case Rep) - "CASE REPORT A 63-year-old woman with stage 3b diabetic kidney disease and depressive disorder was prescribed dulaglutide 0.75 mg/week subcutaneously in August 2023 due to persistent albuminuria despite receiving the maximum tolerated dose of azilsartan...Azilsartan and chlorthalidone could then be successfully rechallenged...Nevertheless, this does not prevent the prescription of GLP-1 RAs to alleviate DKD progression in certain patients. Treatment includes drug discontinuation and steroid therapy in non-responders."

Journal • Acute Kidney Injury • CNS Disorders • Depression • Diabetic Nephropathy • Infectious Disease • Nephrology • Psychiatry • Renal Disease

Molecular mechanisms underlying cyclophosphamide-induced ovarian injury and protective strategies. (PubMed, Naunyn Schmiedebergs Arch Pharmacol) - "Quercetin, resveratrol, berberine, curcumin, irbesartan, mirtazapine, sildenafil, atorvastatin, donepezil, cilostazol, moxibustion, LCZ696, buspirone, levomilnacipran, melatonin, diosmin, and azilsartan are some of the agents that may protect against ovarian injury caused by CP, as shown in Graphical abstract. Our goal in writing this study is to provide a concise overview of the possible redox molecular pathways that cause ovarian harm in CP and how to potentially ameliorate them. Finally, investigation into these molecular pathways may pave the way for early ovarian damage relief and for the development of different agent strategies to alleviate CP-mediated POF."

Journal • Review • Inflammation • Oncology • Women's Health • IL6 • NLRP3 • TNFA

A Case of Thiazide-Induced Hyponatremia in an Elderly Patient. (PubMed, Cureus) - "She was previously taking famotidine, atorvastatin, losartan, triamterene, and atenolol to manage her hypertension and hyperlipidemia. Her medication was changed to azilsartan-chlorthalidone, amlodipine, and carvedilol one week before presentation for better management of her blood pressure...She was followed for two weeks and had been doing well. This case highlights the importance of taking a detailed history and examination, and taking into account drugs as a source of hyponatremia in elderly patients."

Journal • Cardiovascular • Dyslipidemia • Heart Failure • Hypertension

In brief: Low-dose chlorthalidone (HemiClor) for hypertension. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Cardiovascular • Hypertension

CHRONIC KIDNEY DISEASE PROGRESSION ASSESSMENT ON THE BASIS OF COMPLEX TREATMENT (ERA 2025) - "All examined patients individually take the required amount of azilsartan for antihypertensive purposes (40-80 mg/day), depending on the level of hypertension... 1. Application of "additional azylsartan and ethylmetalhydroxypyridine succinate" to conventional treatment slows the development of chronic kidney disease. 2."

Cardiovascular • Chronic Kidney Disease • Hypertension • Nephrology • Renal Disease